DK2384763T3 - Peptidligand til at forstyrre cancercellemigration - Google Patents
Peptidligand til at forstyrre cancercellemigration Download PDFInfo
- Publication number
- DK2384763T3 DK2384763T3 DK11171215.4T DK11171215T DK2384763T3 DK 2384763 T3 DK2384763 T3 DK 2384763T3 DK 11171215 T DK11171215 T DK 11171215T DK 2384763 T3 DK2384763 T3 DK 2384763T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- wnt
- cells
- cell
- adhesion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Formyleret peptid valgt fra gruppen bestående af:
2. Peptid ifølge krav 1, hvor peptidet er formyleret MDGCEL (SEQ. ID. NO: 15).
3. Peptid ifølge krav 1, hvor peptidet er NKTSEGMDGCEL (SEQ. ID. NO: 9), hvor cy-steinet positioneret mellem glycinet og glutaminsyren i peptidet er blevet erstattet med alanin.
4. Farmaceutisk sammensætning indeholdende en terapeutisk virksom mængde af et virksomt formyleret peptid, som er cancercellemotilitetsforstyrrende og valgt fra gruppen bestående af:
eventuelt i kombination med et inert bærestof eller excipiens.
5. Farmaceutisk sammensætning ifølge krav 4, hvor peptidet er formyleret MDGCEL (SEQ. ID. NO: 15).
6. Farmaceutisk sammensætning ifølge krav 4, hvor peptidet er NKTSEGMDGCEL (SEQ. ID. NO: 9), hvor cysteinet positioneret mellem glycinet og glutaminsyren i peptidet er blevet erstattet med alanin.
7. Formyleret peptid valgt fra gruppen bestående af:
til anvendelse i behandling af cancer.
8. Peptid til anvendelse ifølge krav 7, hvor peptidet er formyleret MDGCEL(SEQ. ID. NO: 15).
9. Peptid til anvendelse ifølge krav 7, hvor peptidet er NKTSEGMDGCEL (SEQ. ID. NO: 9) hvor cysteinet positioneret mellem glycinet og glutaminsyren i peptidet er blevet erstattet med alanin.
10. Peptid til anvendelse ifølge et hvilket som helst af kravene 7-9, hvor canceren er brystkræft.
11. Peptid til anvendelse ifølge et hvilket som helst af kravene 7-9, hvor canceren er coloncancer.
12. Anvendelse af et formyleret peptid valgt fra gruppen bestående af:
til fremstilling af en farmaceutisk sammensætning til behandling af cancer ved forstyrrelse af cancercellemotilitet.
13. Anvendelse ifølge krav 12, hvor peptidet er formyleret MDGCEL (SEQ. ID. NO: 15).
14. Anvendelse ifølge krav 12, hvor peptidet er NKTSEGMDGCEL (SEQ. ID. NO: 9) hvor cysteinet positioneret mellem glycinet og glutaminsyren i peptidet er blevet erstattet med alanin.
15. Anvendelse ifølge et hvilket som helst af kravene 12-14, hvor den farmaceutiske sammensætning er til behandling af brystkræft eller coloncancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501204 | 2005-05-30 | ||
| EP06747832.1A EP1888628B1 (en) | 2005-05-30 | 2006-05-30 | A peptide ligand to impair cancer cell migration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2384763T3 true DK2384763T3 (da) | 2015-07-20 |
Family
ID=37481920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11171215.4T DK2384763T3 (da) | 2005-05-30 | 2006-05-30 | Peptidligand til at forstyrre cancercellemigration |
| DK06747832.1T DK1888628T3 (da) | 2005-05-30 | 2006-05-30 | En peptidligand til forstyrrelse af cancercellemigration |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06747832.1T DK1888628T3 (da) | 2005-05-30 | 2006-05-30 | En peptidligand til forstyrrelse af cancercellemigration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8674060B2 (da) |
| EP (2) | EP2384763B1 (da) |
| JP (1) | JP4942745B2 (da) |
| CN (1) | CN101189258B (da) |
| AU (1) | AU2006253056B2 (da) |
| CA (1) | CA2609221C (da) |
| DK (2) | DK2384763T3 (da) |
| ES (2) | ES2530263T3 (da) |
| WO (1) | WO2006130082A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009243233A1 (en) * | 2008-04-30 | 2009-11-05 | Wntresearch Ab | Restoration of estrogen receptor-alpha activity |
| JP5583668B2 (ja) * | 2008-08-13 | 2014-09-03 | ウントレサーチ・エービー | メラノーマおよび胃癌の治療のためのＷｎｔ５−ａペプチド誘導体の使用 |
| EP2226080A1 (en) * | 2009-03-05 | 2010-09-08 | Universiteit Maastricht | Antagonistic peptides for frizzled-1 and frizzled-2 |
| EP2726880B1 (en) | 2011-07-01 | 2019-04-17 | Wntresearch AB | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
| WO2016092378A1 (en) | 2014-12-10 | 2016-06-16 | Angelo Luigi Vescovi | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors |
| ES2963914T3 (es) * | 2017-10-25 | 2024-04-03 | Wntresearch Ab | Péptidos de WNT5A en la reducción de células madre cancerosas |
| EP3613757A1 (en) | 2018-08-20 | 2020-02-26 | Wntresearch AB | Solution phase routes for wnt hexapeptides |
| EP3666789A1 (en) | 2018-12-14 | 2020-06-17 | Wntresearch AB | Linear solution phase routes for wnt hexapeptides |
| KR20220050835A (ko) * | 2019-04-16 | 2022-04-25 | 더블유엔티리서치 에이비 | 암 치료에 사용하기 위한 면역 체크포인트 억제제와 조합된 펩타이드 |
| PL4176901T3 (pl) | 2021-12-10 | 2024-04-08 | Wntresearch Ab | Stabilne kompozycje heksapeptydu foxy-5 o wysokiej rozpuszczalności zawierające zasadę azotową |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000031261A2 (en) * | 1998-11-25 | 2000-06-02 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor |
| EP1033405A3 (en) * | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| WO2001032708A1 (en) * | 1999-11-05 | 2001-05-10 | Forskarpatent I Syd Ab | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
| JP5583668B2 (ja) * | 2008-08-13 | 2014-09-03 | ウントレサーチ・エービー | メラノーマおよび胃癌の治療のためのＷｎｔ５−ａペプチド誘導体の使用 |
| EP2226080A1 (en) * | 2009-03-05 | 2010-09-08 | Universiteit Maastricht | Antagonistic peptides for frizzled-1 and frizzled-2 |
-
2006
- 2006-05-30 ES ES06747832.1T patent/ES2530263T3/es active Active
- 2006-05-30 CN CN2006800191977A patent/CN101189258B/zh active Active
- 2006-05-30 AU AU2006253056A patent/AU2006253056B2/en active Active
- 2006-05-30 EP EP20110171215 patent/EP2384763B1/en active Active
- 2006-05-30 ES ES11171215.4T patent/ES2543473T3/es active Active
- 2006-05-30 JP JP2008514590A patent/JP4942745B2/ja active Active
- 2006-05-30 CA CA2609221A patent/CA2609221C/en active Active
- 2006-05-30 DK DK11171215.4T patent/DK2384763T3/da active
- 2006-05-30 WO PCT/SE2006/000638 patent/WO2006130082A1/en active Application Filing
- 2006-05-30 EP EP06747832.1A patent/EP1888628B1/en active Active
- 2006-05-30 DK DK06747832.1T patent/DK1888628T3/da active
-
2007
- 2007-11-28 US US11/946,303 patent/US8674060B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008542368A (ja) | 2008-11-27 |
| EP2384763A1 (en) | 2011-11-09 |
| JP4942745B2 (ja) | 2012-05-30 |
| US20080207521A1 (en) | 2008-08-28 |
| ES2543473T3 (es) | 2015-08-19 |
| CA2609221A1 (en) | 2006-12-07 |
| CA2609221C (en) | 2014-07-08 |
| AU2006253056B2 (en) | 2012-03-01 |
| DK1888628T3 (da) | 2015-02-02 |
| US8674060B2 (en) | 2014-03-18 |
| CN101189258A (zh) | 2008-05-28 |
| EP1888628B1 (en) | 2014-11-12 |
| EP1888628A1 (en) | 2008-02-20 |
| WO2006130082A1 (en) | 2006-12-07 |
| ES2530263T3 (es) | 2015-02-27 |
| AU2006253056A1 (en) | 2006-12-07 |
| EP2384763B1 (en) | 2015-04-29 |
| CN101189258B (zh) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2384763T3 (da) | Peptidligand til at forstyrre cancercellemigration | |
| US7563596B2 (en) | Method of modulating tissue growth using Frzb protein | |
| ES2770361T3 (es) | Un polipéptido antagonista del receptor 4 de quimiocina CXC (CXCR4) | |
| EP2851084B1 (en) | Modulation of the Vps10p-domain receptors for the treatment of cardiovascular disease | |
| Grundemar et al. | Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes | |
| US20170318057A1 (en) | Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease | |
| CA2739679A1 (en) | Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor | |
| WO2013183494A1 (ja) | 好中球活性化に起因する疾患の治療薬、治療方法及び検査方法 | |
| CZ151696A3 (en) | Bmp receptor encoding dna sequence | |
| US20090155928A1 (en) | Modulating robo: ligand interactions | |
| US20060149050A1 (en) | Isolation and method of using tissue growth-inducing Frzb | |
| Sonavane et al. | Controlling Wnt signaling specificity and implications for targeting WNTs pharmacologically | |
| JP5673912B2 (ja) | 弾性線維再生剤 | |
| WO2016017844A1 (ko) | 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도 | |
| ES2245048T3 (es) | Factor de crecimiento derivado de cadherina y su uso. | |
| WO2021052277A1 (zh) | 重组人神经调节蛋白衍生物及其用途 | |
| JP2003512291A (ja) | ガレクチン１１ | |
| CN105906691A (zh) | 一种Eph激酶多肽抑制剂及其应用 | |
| JP3951676B2 (ja) | オリゴペプチド | |
| JP2003146998A (ja) | 生理活性ペプチド | |
| KR20050053628A (ko) | 혈관신생 및 심혈관형성의 촉진 또는 억제 방법 |